For drugs with low solubility or bioavailability, Capsugel Dosage Form Solutions offers a wide range of formulation options and technologies that maximize the opportunity for development and commercial success of drug candidates.
Our spray-dried nanoadsorbate (SDNA) technology offers another option for improving the bioavailability of drug compounds. SDNAs consist of solid amorphous dispersions adsorbed to the surface of a high-surface-area insoluble material, such as fumed silica and silicon dioxide. This approach greatly increases the surface area of the dispersion relative to normal dispersion particles, leading to rapid dissolution of the drug and resulting in improved bioavailability relative to crystalline drug.
Scanning Electron Microscopy (SEM) Analysis of SDNA Formulations:
Illustration and Transmission Electron Microscopy (TEM) Analysis of SDNA Formulations Containing Various Drug Loadings:
SDNAs are made using a spray-drying process. During the process, the drug and polymer are dissolved in a solvent, while the high surface-area insoluble material is suspended in the spray solution. The suspension is then spray-dried to form solid particles containing the SDNAs. The SDNAs can then be incorporated into solid dosage forms, such as tablets and capsules, for immediate- or modified-release, depending on the desired therapeutic profile.
SDNAs offer several advantages for formulating mixtures of drugs, mixtures of drug and surfactants,
- liquid/lipid formulations, and semi-solid formulations, including:
- better physical stability than pure amorphous formulations,
- stabilization of drugs that tend to crystallize rapidly,
- better bioavailability than crystalline drug or large amorphous particles,
- faster drug dissolution than crystalline drug forms, and
- suitability for use in solid dosage forms and combination products (liquid and semi-solid drug formulations).